Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

Jared Kelly on Immune Priming & Survival Outcomes: Oncolytics Biotech’s Vision for Pelareorep
Shots:  Oncolytics Biotech is advancing pelareorep beyond the traditional standalone therapy model, positioning the platform as a potential immune-priming backbone capable of enhancing immunotherapies, checkpoint inhibitors, chemotherapies, and other oncology treatments across multiple difficult-to-treat tumor settings.  The company continues generating growing survival and immune-engagement data across colorectal, pancreatic, and anal cancers, while emphasizing pelareorep’s potential to “turn cold tumors…
2 days ago
Advancing HES Care with AstraZeneca’s FASENRA: Insights from James Teague & Princess U. Ogbogu
Shots:  Could a targeted biologic therapy help address the longstanding unmet needs in hypereosinophilic syndrome (HES)? AstraZeneca’s FASENRA has now received US approval for HES, introducing a once-monthly treatment option for patients living with this rare and often underdiagnosed eosinophilic disorder  Results from the Phase III NATRON trial showed that FASENRA reduced the risk of first HES flare by 65% vs placebo,…
4 days ago
Roy Maute on Macrophage Checkpoint Inhibition: Pheast’s Vision for Advancing PHST001 in Solid Tumors 
Shots:  Pheast Therapeutics is redefining innate immunity in oncology with PHST001, an anti-CD24 macrophage checkpoint inhibitor engineered to overcome the limitations of earlier macrophage-targeted therapies and unleash a powerful anti-tumor immune response.  At AACR 2026, PHST001 delivered encouraging early clinical signals with favorable tolerability, clear immune activation, and promising anti-tumor responses across heavily pretreated solid tumor…
May 27, 2026
Dr. Orla Cloak on Manufacturing Excellence: Minaris Vision for Advanced Therapies
Shots:  Minaris is advancing its dual-business strategy through specialized Advanced Therapies and Advanced Testing units, enabling sponsors to streamline development, manufacturing, biosafety testing, and commercialization within one integrated global organization.   Minaris is focused on solving key cell & gene therapy manufacturing challenges by reducing variability, accelerating tech transfer, improving “first time right” execution, and lowering…
May 18, 2026
Ending Prescription Ping-Pong in Specialty Care: Colin Banas, CMO, Timely By DrFirst Shares His Vision  
Shots:  Specialty medication access remains challenged by high costs, fragmented workflows, complex prior authorization requirements, and limited transparency, leading to delays, prescription drop-offs, and suboptimal patient outcomes.  DrFirst is addressing these gaps through AI-powered, workflow-integrated solutions that enable real-time benefits verification, targeted prior authorization automation, and smarter pharmacy routing, shifting care from reactive problem-solving to proactive, frictionless prescribing.  PharmaShots welcomes…
May 4, 2026
Jena Sophia on Breaking the Stress Code: Rewiring High Performance from Within 
Shots:  High performers often operate under a hidden layer of chronic stress, where sustained pressure subtly erodes decision-making, creativity, and emotional regulation, as subconscious patterns and past experiences continuously trigger a low-grade fight-or-flight response that impacts both performance and overall wellbeing  Lasting stress management requires going beyond surface-level techniques to address deep-rooted subconscious programming, where beliefs around identity, success,…
April 20, 2026
Innovation Meets Impact: Jaime Leija on BioLab’s Patient-First Approach
Shots:  BioLab balances innovation with real-world impact through a dual strategy that combines rapid commercialization of FDA-approved or near-market solutions like Imbed with continued investment in long-term innovations such as cureVision and terraplasma, ensuring both immediate clinical needs and future breakthroughs in wound care are effectively addressed.    BioLab’s growth is driven by sharp strategic discipline, focusing on chronic outpatient…
April 13, 2026
When Algorithms Decide Visibility: Ben Beckley, CEO of RevHealth on the Future of Pharma 
Shots:  AI is redefining visibility in pharma as it becomes the primary gateway to information, requiring companies to shift from content publishing to engineering discoverability with machine-readable, well-cited, and rapidly updated data to be included in AI-generated summaries  Integrated, structured evidence is now critical for success in AI-driven environments, demanding modular, metadata-rich, and consistent data…
April 6, 2026
Turning Genome Data into Clinical Insight: Jehee Suh of Inocras on AI-Driven Genomics 
Shots:  Inocras is advancing the clinical adoption of whole-genome sequencing (WGS) by transforming it from a research tool into a standardized diagnostic workflow, refining its algorithms through thousands of real-world patient cases to deliver actionable genomic insights in routine care.  Through platforms such as CancerVision, RareVision, and MRDVision, the company integrates deep genomic analytics, AI-driven bioinformatics, and clinical services like genetic counseling and…
March 31, 2026
Triple Therapy Momentum: Caterina Brindicci of AstraZeneca on Breztri in Asthma
Shots:   AstraZeneca is exploring the potential of Breztri Aerosphere in uncontrolled asthma, aiming to address the large proportion of patients who remain symptomatic on standard dual therapy and improve lung function and quality of life.  Findings from the KALOS and LOGOS Phase III trials revealed meaningful lung function gains and a 14% reduction in severe exacerbations versus dual ICS/LABA therapy, highlighting the promise of triple…
March 30, 2026
Load more